A5081208468- Hemophilia Treatment and Research
- Platelet Disorders and Treatments
- Cardiovascular Issues in Pregnancy
- Maternal and fetal healthcare
- Connective tissue disorders research
- Blood Coagulation and Thrombosis Mechanisms
- Uterine Myomas and Treatments
- Venous Thromboembolism Diagnosis and Management
- Endometriosis Research and Treatment
- Pregnancy and preeclampsia studies
- Vasculitis and related conditions
- Chronic Myeloid Leukemia Treatments
- Colorectal Cancer Screening and Detection
- Atrial Fibrillation Management and Outcomes
- Translation Studies and Practices
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Bladder and Urothelial Cancer Treatments
- Ectopic Pregnancy Diagnosis and Management
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Systemic Lupus Erythematosus Research
- Neutrophil, Myeloperoxidase and Oxidative Mechanisms
- Urinary and Genital Oncology Studies
- Medical and Biological Sciences
- Case Reports on Hematomas
- Ovarian function and disorders
University of Colorado Anschutz Medical Campus
2018-2023
University of Colorado Denver
2020-2023
Children's Hospital Colorado
2023
University of Colorado System
2022
University of Colorado Hospital
2020
Saint Louis University
2011
Emicizumab, a bispecific antibody factor VIII mimetic, is approved for prophylaxis in hemophilia, and has different risks side effects compared to products.
Venous thromboembolism (VTE) is a highly morbid condition with several available oral anticoagulant treatment options. Numerous studies have been published comparing warfarin to direct anticoagulants; however, populations remain underrepresented in these reports. We surveyed members of The ThromboEmbolism Network U.S. working group regarding their preferences for the VTE different and challenging populations. In individuals no other medical comorbidities, respondents preferred either...
Acquired hemophilia A (AHA) is a disease caused by antibody formation inhibiting the function of factor VIII, causing bleeding. Recombinant porcine VIII (rpFVIII) escapes human FVIII recognition and can provide life-saving hemostasis. However, development antibodies against pFVIII limit its use. We report two cases in which loss response to rpFVIII occurred, likely because antibodies. In case 1, patient achieved hemostasis but lost within few days. second case, controlled bleeding...
<b><i>Introduction:</i></b> In response to the increasing complexity of care for patients with bleeding disorders, we established new clinical teams our hemophilia treatment center (HTC). <b><i>Aims:</i></b> We undertook a quality improvement project improve coordination and communication by establishing primary assignments staff individual (primary teams). <b><i>Methods:</i></b> A group was formed that goals assignment...